NL930110I1 - Carbazolyl-(4)-oxypropanolamine-derivaten werkwijze ter bereiding daarvan en geneesmiddelen die dezeverbindingen bevatten - Google Patents

Carbazolyl-(4)-oxypropanolamine-derivaten werkwijze ter bereiding daarvan en geneesmiddelen die dezeverbindingen bevatten

Info

Publication number
NL930110I1
NL930110I1 NL930110C NL930110C NL930110I1 NL 930110 I1 NL930110 I1 NL 930110I1 NL 930110 C NL930110 C NL 930110C NL 930110 C NL930110 C NL 930110C NL 930110 I1 NL930110 I1 NL 930110I1
Authority
NL
Netherlands
Prior art keywords
carbazolyl
compounds
preparation
medicaments containing
oxypropanolamine
Prior art date
Application number
NL930110C
Other languages
English (en)
Other versions
NL930110I2 (nl
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL930110(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NL930110I1 publication Critical patent/NL930110I1/nl
Publication of NL930110I2 publication Critical patent/NL930110I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL930110C 1978-04-13 1993-06-29 Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten. NL930110I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
NL930110I1 true NL930110I1 (nl) 1993-10-18
NL930110I2 NL930110I2 (nl) 1994-12-01

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
NL930110C NL930110I2 (nl) 1978-04-13 1993-06-29 Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten.

Country Status (23)

Country Link
US (1) US4503067A (nl)
EP (1) EP0004920B1 (nl)
JP (2) JPS54157558A (nl)
AT (1) AT375639B (nl)
AU (1) AU522975B2 (nl)
BG (1) BG61419B2 (nl)
CA (1) CA1129416A (nl)
CS (2) CS227007B2 (nl)
DD (1) DD143607A5 (nl)
DE (2) DE2815926A1 (nl)
DK (1) DK154555C (nl)
ES (1) ES479396A1 (nl)
FI (1) FI70406C (nl)
HK (1) HK2385A (nl)
HU (1) HU179433B (nl)
IL (1) IL57020A (nl)
LT (1) LT2628B (nl)
LU (1) LU88320I2 (nl)
MX (1) MX9203380A (nl)
NL (1) NL930110I2 (nl)
SG (1) SG52284G (nl)
SU (1) SU810079A3 (nl)
ZA (1) ZA791732B (nl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US20030036980A1 (en) * 2001-08-14 2003-02-20 Wren Stephen C. System for marketing goods and services utilizing computerized central and remote facilities
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
AU4083097A (en) * 1996-08-23 1998-03-06 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Method for inhibiting the expression of fas
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
CZ123099A3 (cs) * 1996-10-09 1999-11-17 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corporation Limited Partnership No. 1 Farmaceutický prostředek pro inhibici stresem-aktivovaných protein kinas
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
AU751117B2 (en) * 1997-11-12 2002-08-08 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Novel oral dosage form for carvedilol
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
AU3522399A (en) * 1998-04-09 1999-11-01 Roche Diagnostics Gmbh Carvedilol-galenics
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
CA2402336C (en) * 2000-04-03 2008-03-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
US6699997B2 (en) * 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
JP2004525941A (ja) * 2001-04-02 2004-08-26 スミスクライン・ビーチャム・コーポレイション 治療方法
IN191028B (nl) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
JP2004534840A (ja) * 2001-07-13 2004-11-18 スミスクライン・ビーチャム・コーポレイション カルベジロール多型体
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
RU2308449C2 (ru) * 2001-09-28 2007-10-20 Ф.Хоффманн-Ля Рош Аг Псевдополиморфные формы карведилола
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CA2483054A1 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US20050261335A1 (en) * 2002-05-03 2005-11-24 Wei Chen Carvedilol formulations
CA2484624A1 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
KR20040010306A (ko) * 2002-07-22 2004-01-31 (주)나노하이브리드 이트라코나졸, 사이클로스포린 또는 카르베딜올과 층상형규산염의 혼성체 및 그 제조 방법
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
WO2004106299A2 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2004113296A1 (en) * 2003-06-20 2004-12-29 Sun Pharmaceutical Industries Limited A process for preparation of 1-[9h-carbazol-4-yloxy]- 3-[{2-(2-(-(methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
EP1691789B1 (en) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070191456A1 (en) * 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
JP2008523025A (ja) * 2004-12-09 2008-07-03 ザック システム エス．ピー．エー． カルベジロール及びそのエナンチオマーの調製プロセス
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
BRPI0617364A2 (pt) * 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
EP1991527A2 (en) * 2006-06-28 2008-11-19 Teva Pharmaceutical Industries Ltd Polymorphous forms of carvedilol phosphate
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2195292B1 (en) * 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009035535A2 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
ATE539769T1 (de) * 2008-03-04 2012-01-15 Lupin Ltd Stabile pharmazeutische zusammensetzungen mit carvedilol
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
EP2791199B1 (en) 2011-12-16 2015-09-16 3M Innovative Properties Company Oxirane-containing bisanhydrohexitol derivatives and uses thereof
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives

Also Published As

Publication number Publication date
EP0004920B1 (de) 1981-08-05
AT375639B (de) 1984-08-27
ES479396A1 (es) 1980-04-16
EP0004920A1 (de) 1979-10-31
JPH0123462B2 (nl) 1989-05-02
SU810079A3 (ru) 1981-02-28
ATA276279A (de) 1984-01-15
CS227007B2 (en) 1984-04-16
NL930110I2 (nl) 1994-12-01
DE2960553D1 (en) 1981-11-05
AU4582079A (en) 1979-10-18
DK154555B (da) 1988-11-28
DK141979A (da) 1979-10-14
DK154555C (da) 1989-06-19
LU88320I2 (de) 1994-05-04
JPS63258416A (ja) 1988-10-25
CA1129416A (en) 1982-08-10
SG52284G (en) 1985-03-29
FI70406B (fi) 1986-03-27
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
BG61419B2 (bg) 1997-07-31
CS420091A3 (en) 1992-04-15
AU522975B2 (en) 1982-07-08
DD143607A5 (de) 1980-09-03
FI791142A (fi) 1979-10-14
IL57020A (en) 1982-07-30
HU179433B (en) 1982-10-28
MX9203380A (es) 1992-09-01
ZA791732B (en) 1980-05-28
LT2628B (lt) 1994-04-25
JPS54157558A (en) 1979-12-12
DE2815926A1 (de) 1979-10-18
US4503067A (en) 1985-03-05
FI70406C (fi) 1986-09-19

Similar Documents

Publication Publication Date Title
NL930110I1 (nl) Carbazolyl-(4)-oxypropanolamine-derivaten werkwijze ter bereiding daarvan en geneesmiddelen die dezeverbindingen bevatten
NL7902489A (nl) Cycloalkyltriazoolderivaten met farmacologische wer- king, werkwijze ter bereiding van deze verbindingen, alsmede gedoseerde farmaceutische preparaten die zo'n verbinding bevatten.
CS410191A3 (en) Benzimidazoles, process of their preparation and medicaments comprising said compounds
NL930032I1 (nl) 7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-naftyridine-3-carbonzuren werkwijzen ter bereiding ervan en deze bevattende geneesmiddelen
IL56411A0 (en) New derivatives of 4-amino-5-alkylsulphonyl-ortho-anisamides, their preparation and pharmaceutical compositions containing them
PH18091A (en) Novel spiro-oxazolidindiones,pharmaceutical compositions containing same and method of use thereof
SE8001747L (sv) Forfarande for framstellning av 1-fluorerade vitamin d-foreningar
ZA777532B (en) 1,4-dihydropyridine compounds,process for preparation thereof and pharmaceutical composition of the same
PT69821A (en) Process for the preparation of new 5-phenylpyrazole derivatives the salts thereof and the pharmaceutical compositions containing same
NZ191462A (en) Derivatives of 2 ,16 -bis-piperidino-3 -hydroxy-5 -androstane-3 -esters
IT1209143B (it) Derivati di 7-osso-4-tia-1-aza-biciclo-[3,2,0]eptano
NO790061L (no) Nye derivater av 1-aza-(2,2,2)-bicyklooktan
IT1193847B (it) Composizione farmaceutica contenente 3,4-di-idro-3-osso-2-chinossaline
NL7811050A (nl) Nieuwe chinazolinederivaten, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die zo'n verbinding bevatten.
ZA792773B (en) Derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid
PH13924A (en) Glavulanic acid derivatives,pharmaceutical compositions containing same and method of preparation thereof
ZA784471B (en) Derivatives of 1,3-diphenoxypropane-2-on,process for their preparation,medicaments thereof,and their use as medicaments
PH14398A (en) Pharmaceutical compounds,compositions containing same and method of use
RO81506A (ro) Procedeu pentru prepararea derivatilor acizilor 1,3,4-tiadiazol-2-carboxilici
JPS5295690A (en) Derivatives of 33carbamoyloxymethyll 77*aminoo44thiazolylacetoamide* cephalospolanate process for preparing same and pharmaceutical compound
GB2036737B (en) Derivatives of 1,5-dimethylbicyclo(3,2,1)octaine
NL7900721A (nl) Nieuwe derivaten van 1-naftylazijnzuur, werkwijze ter bereiding daarvan en farmaceutische preparaten, die deze verbindingen bevatten.
RO81936A (ro) Procedeu pentru prepararea unor derivati ai acidului 7 beta-aminotiazolilacetamido-3-cefem-4-carboxilic
IL56815A (en) Epimerisation of 3-vinylpiperidine derivatives
IT1101712B (it) Procedimento perfezionato per la preparazione di guaiacolo acetil-salicilato